Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Jardiance | empagliflozin | Heart failure | Reimburse with clinical criteria and/or conditions | Complete | ||
Jemperli | dostarlimab | Endometrial cancer | Do not reimburse | Complete | ||
Jemperli | dostarlimab | Endometrial cancer | Pending | |||
Jemperli | dostarlimab | Endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Jentadueto | Linagliptin-metformin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
Jetrea | Ocriplasmin | Vitreomacular adhesion | List with criteria/condition | Complete | ||
Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | ||
Jorveza | budesonide | Eosinophilic esophagitis, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Jorveza | budesonide | Maintenance of Eosinophilic esophagitis in adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Jublia | efinaconazole | Onychomycosis | Do not reimburse | Complete |